Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has appointed a new auditor, Crowe Horwath, for the fiscal year ending December 31, 2024, following an independent evaluation process by its audit committee [1] Group 1 - The audit committee conducted an independent and objective assessment of the selection process, tendering procedures, and the professional competence, capability, integrity, and independence of the proposed auditing firm [1] - The audit committee concluded that Crowe Horwath is qualified and suitable to serve as the company's auditor for the specified period [1] - The board of directors has resolved to recommend the appointment of Crowe Horwath as the new auditor based on the audit committee's suggestions [1]

智通财经APP讯，山东新华制药股份(00719)公布2023年业绩，营业收入约81亿元，同比增长7.97%;归属 于上市公司股东的净利润约4.965亿元，同比增长20.79%;基本每股收益0.74元，末期股息每股0.25 元(含 税)。 原料药国际市场主导产品市场及价格保持基本稳定;国内市场充分发挥综合优势，收入、利润同比实现 大幅增长。4 个制剂产品集采中标，18 个产品各项联盟集采中标。制剂加工和出口业务全年销售收入同 比增长 48.73%。医贸商业顺利通过现代医药物流资质认证。新华健康加快开拓双向跨境业务及自有品 牌打造，收入同比增长 21.16%。全年共有 18 个新产品投放市场。产品技术改造项目、强链固链项目加 快推进。 ...

Financial Performance - The total operating revenue for 2023 reached RMB 8,100,844,707.33, representing a 7.97% increase from RMB 7,502,987,102.09 in 2022[3] - The net profit attributable to shareholders of the listed company was RMB 496,512,201.25, an increase of 20.79% compared to RMB 411,063,056.58 in the previous year[3] - The basic earnings per share for 2023 was RMB 0.74, reflecting a 19.35% increase from RMB 0.62 in 2022[3] - The company reported a total profit of RMB 532,685,725.02, compared to RMB 471,774,350.61 in 2022, marking an increase of 12.9%[42] - The company’s gross profit margin for the year was approximately 29.0%, calculated from total revenue and cost of goods sold[61] - The total tax and additional charges for 2023 were RMB 92,175,276.66, an increase from RMB 65,309,856.07 in 2022, reflecting a growth of approximately 41%[63] Assets and Liabilities - The total assets as of the end of 2023 amounted to RMB 8,286,166,330.90, showing a slight increase of 0.26% from RMB 8,264,790,395.98 in 2022[4] - The total liabilities decreased by 10.34% to RMB 3,510,413,044.14 from RMB 3,915,226,169.32 in the previous year[4] - Current assets totaled RMB 3,314,333,616.01, down from RMB 3,456,959,427.88 in the previous year, reflecting a decrease of approximately 4.1%[40] - The company’s total non-current assets increased to RMB 4,971,832,714.89 from RMB 4,807,830,968.10, reflecting a growth of approximately 3.4%[40] - The company’s equity attributable to shareholders increased to RMB 4,553,103,869.56 from RMB 4,126,274,379.52, indicating a growth of approximately 10.3%[41] Cash Flow - The cash flow from operating activities was RMB 265,278,895.87, a significant decrease of 65.01% compared to RMB 758,240,601.50 in 2022[3] - Operating cash inflow for 2023 was RMB 7,057,191,280.19, a decrease of 0.80% compared to 2022[22] - Net cash flow from operating activities decreased by 65.01% to RMB 265,278,895.87 due to increased customer payment terms and fulfillment of contracts from previous year[23] - Investment cash outflow increased by 32.84% to RMB 325,133,303.80, primarily due to increased project investments[23] - Financing cash inflow decreased by 25.51% to RMB 868,447,154.49, attributed to reduced fundraising from non-public A-share issuance and increased dividend payments[23] Shareholder Information - As of December 31, 2023, the total number of shareholders was 97,594, including 39 H-share shareholders and 97,555 A-share shareholders[7] - The largest shareholder, Hualu Holdings Group Co., Ltd., held 30.36% of the shares, totaling 204,864,092 shares[8] - The total number of shares issued by the company is 682,407,635, which includes 487,407,635 A shares and 195,000,000 H shares[11] - The proposed final dividend for the year 2023 is RMB 0.25 per share, subject to shareholder approval[11] - The weighted average number of ordinary shares outstanding increased to 674,287,215.00 in 2023 from 660,602,072.00 in 2022, representing a growth of about 2.9%[67] Operational Highlights - The company's main business involves the development, manufacturing, and sales of chemical raw materials, formulations, and pharmaceutical intermediates[15] - The company achieved a sales revenue growth of 48.73% in the formulation processing and export business year-on-year[27] - A total of 18 new products were launched in the market during the year, with 26 drug approvals and 15 veterinary drug approvals, setting a historical high[27] - The company successfully passed 195 quality audits and inspections, achieving zero quality incidents for the year[28] - The company has been recognized as a model factory for intelligent manufacturing and a leading enterprise in talent development in Shandong Province[28] Research and Development - R&D expenses increased by 21.29% to ¥419,239,700.90 from ¥345,658,511.77[20] - The company is focusing on enhancing the quality and reducing costs of pharmaceutical intermediates to support raw material drug development[30] - The company plans to accelerate the development of the EPA series and other specialty raw materials to achieve sales growth in both international and domestic markets[30] - The company aims to obtain over 10 formulation approvals, 3 raw material drug approvals, and 5 consistency evaluation approvals in 2024[30] Employee Information - The company reported a total employee count of 7,104 and total employee compensation of RMB 743,778 thousand for the year 2023[32] - The total provision for employee benefits increased significantly, reflecting the company's commitment to employee welfare and retention strategies[56] - Short-term employee compensation increased significantly from RMB 95,171,404.13 to RMB 123,985,296.73, reflecting higher labor costs or expanded workforce[55] Market and Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[44] - The company has implemented two equity incentive plans to enhance the motivation of management and core staff[29] - The company has established a green channel for new product transformation to expedite the market launch process[30]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容 而引致之任何損失承擔任何責任。 山東新華製藥股份有限公司 Shandong Xinhua Pharmaceutical Company Limited （於中華人民共和國註冊成立之股份有限公司） （股份代碼：00719） 截至2023年9月30日止九個月之 未經審核季度業績公告 本公告乃根據《香港聯合交易所有限公司證券上市規則》（「上市規則」）第13.09條及第13.10B條 以及《證券及期貨條例》（香港法例第571章）第XIVA部項下的內幕消息條文（定義見上市規則） 而作出。 山東新華製藥股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈本公司及其附屬公司（「本 集團」）截至2023年9月30日止九個月未經審核的綜合業績。本公告所載之財務資料均按照《中國企 業會計準則》（定義見上市規則）編製並經董事會及董事會審核委員會審視並核准。 本公司董事會、監事會及董事、監事、高級管理人員及主管會計工作負責人保證本公告內容的真實、 準確、完整 ...

山 東 新 華 製 藥 股 份 有 限 公 司 Shandong Xinhua Pharmaceutical Company Limited ( H 股股份代號：00719 ) (Ａ股股份代號：000756 ) 2023 中 期 報 告 目 錄 | --- | --- | |----------------------------------------------------|-------| | | | | 公司基本情況 | 2 | | 按《中國企業會計準則》編製的主要財務數據和財務指標 | 3 | | 股本變動及股東情況 | 6 | | 董事、監事、高級管理人員及員工情況 | 10 | | 董事長報告 | 22 | | 經營管理研討與分析 | 26 | | 重要事項 | 36 | | 公司管治 | 50 | | 財務報告 | 51 | | 備查文件 | 218 | 重要提示 本公司董事會、監事會及董事、監事、高級管理人員保證半年度報告內容的真實、準確、完整，不 存在虛假記載、誤導性陳述或重大遺漏，並承擔個別和連帶的法律責任。 本公司及其附屬公司（「本集團」）截至2023年6月30日止半年度財務報告未經審 ...

Financial Performance - Revenue for the six months ended June 30, 2023, was RMB 4,672,269,049.13, representing a 27.51% increase compared to RMB 3,664,294,993.33 for the same period in 2022[5] - Total profit for the same period was RMB 331,945,812.26, up 41.06% from RMB 235,316,728.47 in the previous year[5] - Net profit attributable to shareholders was RMB 269,807,157.85, reflecting a 38.80% increase from RMB 194,389,556.12 in the prior year[5] - Basic earnings per share increased to RMB 0.40, a rise of 33.33% compared to RMB 0.30 in the same period last year[5] - Operating revenue for the six months ended June 30, 2023, reached RMB 4,672,269,049.13, an increase of 27.51% compared to the same period in 2022[24] - The company's net profit for the six months ended June 30, 2023, was RMB 275,680,432.27, representing a 38.88% increase compared to the same period in 2022[24] - The total profit for the six months ended June 30, 2023, was RMB 331,945,812.26, a 41.06% increase year-on-year, driven by expanded sales scale and improved management efficiency[24] - The company reported a net profit margin for the reporting period of approximately 5.89%, compared to 5.42% in the previous year[5] Assets and Liabilities - The company's total assets as of June 30, 2023, were RMB 8,075,584,581.73, a decrease of 2.29% from RMB 8,265,131,332.13 at the end of 2022[5] - Total liabilities decreased by 9.96% to RMB 3,525,405,717.37 from RMB 3,915,226,169.32 at the end of 2022[5] - The company's total debt amounted to RMB 1,329,244,000, with cash and cash equivalents of RMB 979,173,000[30] - The asset-liability ratio stood at 43.66%, reflecting the company's financial stability[30] - Current assets totaled RMB 3,235,189,305.38, down from RMB 3,456,959,427.88, indicating a decrease of about 6.41%[46] - The company's cash and cash equivalents decreased to RMB 979,173,294.29 from RMB 1,158,741,565.90, a reduction of approximately 15.5%[46] - Total liabilities as of June 30, 2023, were RMB 3,525,405,717.37, down from RMB 3,915,226,169.32 at the end of 2022, indicating a reduction of approximately 9.9%[53][54] Operational Highlights - Domestic sales of active pharmaceutical ingredients (APIs) grew by 78.49% year-on-year, reflecting the company's strong market position[15] - Sales of industrial formulations increased by 48.66% year-on-year, while formulation processing and export business saw a remarkable growth of 93.97%[15] - The company launched 7 new products in the first half of 2023, including 5 formulation products and 1 active pharmaceutical ingredient[15] - A total of 10 drug production approvals and 6 veterinary drug approvals were obtained, marking a historical high for the company[16] - The company is advancing key projects, with construction completed for 4 projects, including DCB and methyldopa, now moving into equipment installation[15] - The company’s commercial segment achieved rapid growth, focusing on both pharmaceutical and non-pharmaceutical sectors[15] Research and Development - Research and development expenses increased by 39.72% year-on-year, totaling RMB 235,529,909.24, reflecting the company's commitment to technological innovation[24] - The company was granted 22 patents, including 8 invention patents, demonstrating its commitment to innovation[16] Cash Flow and Financial Management - The company reported a significant decrease in net cash flow from operating activities, which was RMB 20,131,070.66, down 89.67% from RMB 194,801,492.76 in the previous year[5] - Financial expenses decreased by 90.75% to RMB 1,341,987.35, attributed to optimized financing structure and increased foreign exchange gains[24] - Short-term borrowings rose by 106.31% to RMB 243,494,933.55, indicating a strategy to optimize the debt structure and reduce financing costs[23] Shareholder Information - As of June 30, 2023, the top shareholder, China Hualu Holdings Group Co., Ltd., held 30.36% of the shares, totaling 204,864,092 shares[8] - Hualu Holdings committed not to reduce its shareholding in the company within six months prior to the pricing benchmark date of the non-public A-share issuance[33] - Hualu Holdings promised to avoid any business or activities that may cause competition or conflict of interest with the company's main business during its control period[33] Compliance and Governance - The company has adhered to corporate governance codes during the reporting period without deviation[42] - The audit committee has reviewed the unaudited interim accounts for the six months ending June 30, 2023, and agreed with the financial accounting principles adopted[43] - The company has maintained compliance with the standards set forth in the "Standard Code" regarding securities trading, confirming no violations during the reporting period[45] Future Outlook - The company aims to obtain 6 new product production approvals, 1 raw material production approval, 2 clinical approvals, and 2 consistency evaluation approvals in the second half of the year[20] - The company plans to enhance market driving force by leveraging the diverse specifications of raw materials and expanding both export and domestic sales[19] - The company is actively expanding its pharmaceutical logistics and brand operations to improve profitability and accelerate growth[19] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[70]

Stock Options Incentive Plans - The company reported a total of 10,692,000 stock options granted under the 2018 A-share stock option incentive plan, with 5,167,800 options vested by the end of the reporting period[4]. - No stock options under the 2018 A-share stock option incentive plan have expired during the reporting period[5]. - The company has not granted stock options exceeding 1% of its total issued share capital to any participant, nor more than 0.1% in any 12-month period[5]. - As of December 31, 2022, there were no unvested stock options remaining for the participants under the 2018 plan[5]. - The company granted 9,035,400 stock options to other employee participants, with 4,339,500 options vested by the end of the reporting period[4]. - The company’s stock options have a waiting period of 24, 36, and 48 months, with specific exercise periods defined[5]. - The company’s stock options are structured to allow 34% to be exercised after 24 months, 33% after 36 months, and the remaining 33% after 48 months[5]. - The stock options under the 2021 A-share stock option incentive plan have a waiting period of 24, 36, and 48 months from the grant date, with 34% exercisable after 24 months[10]. - No stock options under the 2021 A-share stock option incentive plan have expired during the reporting period[10]. - The company has not granted or will grant options exceeding 1% of its total issued share capital to any participant, and no more than 0.1% in any 12-month period[10]. Compensation for Executives - The total compensation for key executives amounts to 3,870,000 RMB, with additional employee participants totaling 19,280,000 RMB, leading to a combined total of 23,150,000 RMB for the reporting period[8]. Company Governance - The company aims to further elaborate on its stock option incentive plan following the disclosure of its 2022 annual report[2]. - The company’s board of directors remains unchanged as of the announcement date, with key executives including the chairman and independent directors listed[11]. Stock Option Grants - The company granted 1,750,000 stock options to certain employee participants on December 26, 2022, with an exercise price of 37.53 RMB per share, and a fair value of 14.67 RMB per share at the grant date[9]. - The company has provided a summary of the stock option changes for the 2021 A-share stock option incentive plan, indicating ongoing management of employee incentives[5].

Financial Performance - Operating revenue for Q1 2023 reached RMB 2,639,665,769.78, representing a 44.15% increase compared to RMB 1,831,254,151.22 in Q1 2022[2] - Net profit attributable to shareholders was RMB 151,603,818.36, up 39.72% from RMB 108,503,552.76 in the same period last year[2] - Basic earnings per share increased to RMB 0.23, a rise of 35.29% from RMB 0.17 in Q1 2022[3] - The total comprehensive income for Q1 2023 was RMB 161,720,238.98, compared to RMB 94,819,997.43 in Q1 2022[5] - The company reported a net profit margin of approximately 5.74% for Q1 2023, compared to 5.92% in Q1 2022[4] Cash Flow and Assets - The net cash flow from operating activities showed a significant decline, amounting to (RMB 183,742,803.27), a decrease of 937.28% compared to (RMB 17,713,946.61) in Q1 2022[2] - Total assets as of March 31, 2023, were RMB 7,976,649,915.84, down 3.49% from RMB 8,265,131,332.13 at the end of 2022[3] Equity and Returns - The return on equity (ROE) increased to 3.59%, up 0.52 percentage points from 3.07% in Q1 2022[3] - The total equity attributable to shareholders increased to RMB 4,323,961,931.78, a growth of 4.79% from RMB 4,126,460,390.95 at the end of 2022[3] Research and Development - Research and development expenses for Q1 2023 were RMB 112,119,587.26, reflecting an increase from RMB 78,758,186.08 in Q1 2022[4] Accounting Policy Changes - The company has implemented changes to its accounting policies effective from January 1, 2023, in accordance with the Ministry of Finance's announcement on November 30, 2022[6] - The changes include the treatment of deferred income tax related to assets and liabilities arising from individual transactions, which are not subject to initial recognition exemptions[6] - The board of directors approved the accounting policy changes during the 11th meeting of the 10th board session on April 20, 2023[6]

山 東 新 華 製 藥 股 份 有 限 公 司 Shandong Xinhua Pharmaceutical Company Limited ( H股股份代號：0719 ) ( A股股份代號 : 000756 ) ( H Share Stock Code : 0719 ) ( A Share Stock Code : 000756 ) 2022 Annual Report 年 報 | --- | --- | --- | |----------------------------------------------------------------------------------------------------------------------|-------|--------------------------------------------------------------------------| | | | 目錄 CONTENTS | | 重要提示 | 2 | 公司基本情況簡介 Company Information | | 本公司董事會、監事會及董事、監事、 高級管理人員保證本報告所 ...

Financial Performance - The total revenue for 2022 was RMB 7,502,987,102.09, representing a 14.37% increase from RMB 6,560,077,586.40 in 2021[4]. - The net profit attributable to shareholders of the listed company was RMB 411,193,683.53, an increase of 17.97% compared to RMB 348,548,495.99 in the previous year[4]. - The operating cash flow net amount reached RMB 758,240,601.50, showing a significant increase of 192.62% from RMB 259,116,960.17 in 2021[4]. - The basic earnings per share increased to RMB 0.62, a rise of 10.71% from RMB 0.56 in the previous year[4]. - The diluted earnings per share also increased to RMB 0.61, reflecting an 8.93% growth compared to RMB 0.56 in 2021[4]. - The total comprehensive income for the year was RMB 413,373,076.38, up from RMB 313,908,790.25 in 2021, showing a growth of 31.69%[49]. - The operating profit for the year ended December 31, 2022, was RMB 476,706,533.91, compared to RMB 425,590,536.88 in 2021, indicating an increase of about 12.0%[54]. Assets and Liabilities - Total assets as of December 31, 2022, were RMB 8,265,131,332.13, up 12.73% from RMB 7,332,033,657.98 at the end of 2021[5]. - The total liabilities increased by 6.37% to RMB 3,915,226,169.32 from RMB 3,680,888,823.85 in the previous year[5]. - The net assets attributable to shareholders of the listed company rose by 18.99% to RMB 4,126,460,390.95 from RMB 3,467,941,567.45 in 2021[5]. - Current liabilities totaled RMB 3,158,485,539.10 as of December 31, 2022, compared to RMB 2,501,880,371.20 in 2021, indicating a significant increase of 26.29%[47]. - Long-term borrowings increased to RMB 545,655,801.48 in 2022 from RMB 346,196,870.64 in 2021, representing a growth of 57.67%[47]. Shareholder Information - As of December 31, 2022, the total number of shareholders was 107,300, including 38 H-share shareholders and 107,262 A-share shareholders[8]. - The proposed final dividend for the year 2022 is RMB 0.20 per share (before tax), subject to shareholder approval[12]. - The largest shareholder, China Hualu Holdings Group Co., Ltd., holds 30.59% of the shares, totaling 204,864,092 shares[10]. - The company emphasizes the importance of shareholder approval for the proposed dividend distribution[12]. - The proposed dividend for 2022 represents a 33.33% increase compared to the previous year's dividend[81]. Cash Flow and Investments - Cash and cash equivalents increased by 55.61% to RMB 1,158,741,565.90 compared to RMB 744,662,302.34 last year, primarily due to net proceeds from a non-public offering of A-shares amounting to RMB 244 million and an increase in customer prepayments[18][20]. - Net cash flow from operating activities reached RMB 758,240,601.50, a substantial increase of 192.62% compared to RMB 259,116,960.17 last year[23][24]. - The company achieved a fixed asset investment of RMB 720 million for the year, representing a year-on-year increase of 21%[30]. Research and Development - Research and development expenses increased by 1.26% to RMB 345,658,511.77 from RMB 341,367,394.20, reflecting ongoing investment in innovation[21]. - The company obtained 7 new product approvals for formulations and 4 for raw materials in 2022, including significant breakthroughs in drug innovation[29]. - The company plans to accelerate the development of new products, focusing on fish oil, hormones, and other specialty raw materials[33]. Market Performance - The sales revenue of the top 10 strategic formulations increased by 30% year-on-year, with the sales of fish oil soft capsules exceeding RMB 10 million[29]. - The international formulations and contract manufacturing sales saw an impressive year-on-year growth of 88%[29]. - The revenue from external transactions for the chemical raw materials segment was RMB 3,171,564,382.95 for the year ended December 31, 2022, compared to RMB 2,740,737,136.77 in 2021, marking an increase of approximately 15.7%[53]. Operational Efficiency - The company achieved a receivables turnover rate of 1,056.89% and an inventory turnover rate of 488.11% as of December 31, 2022[26]. - The company aims to enhance production efficiency and cost control through lean production and procurement management strategies[37]. - The company completed 30 technical quality projects and 21 energy transformation projects, saving RMB 20.9 million in raw material and energy consumption[30]. Compliance and Governance - The audit for the financial statements was conducted by Shinewing Certified Public Accountants, ensuring compliance with Chinese accounting standards[39]. - The company has established an audit committee to oversee financial reporting and internal controls, meeting four times during the year[44].